The twice-yearly shot was 100% effective in preventing HIV infections in a study of women, and results published Wednesday ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...

Following the promising multicentre, international Purpose 1 and Purpose 2 clinical trials with lenacapavir for HIV ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. But it needs to be cheaper to be effective.When lenacapavir test results were presented at a World AIDS ...

Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It ...

While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal ...

Gilead's twice-yearly HIV prevention shot was 100% effective in women and almost as good in men. The company will offer cheap ...

Gilead Sciences has announced the outcomes from the randomised Phase III PURPOSE 2 trial evaluating lenacapavir for human immunodeficiency virus (HIV) prevention. The trial demonstrated a 96% ...